DOI QR코드

DOI QR Code

A Case of Systemic Lupus Erythematosus Manifested as Anemia and Thrombocytopenia during Antithyroid Drug Treatment

항갑상선제 치료 중 빈혈과 혈소판감소증으로 발현된 전신성홍반성낭창

  • Kim, Da-Ham (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Park, Hee-Jin (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Kim, Young-Sook (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Choi, Eun-Yeong (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Lee, Sang-Won (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Lee, Eun-Jig (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Shin, Dong-Yeob (Department of Internal Medicine, Yonsei University College of Medicine)
  • 김다함 (연세대학교 의과대학 내과학교실) ;
  • 박희진 (연세대학교 의과대학 내과학교실) ;
  • 김영숙 (연세대학교 의과대학 내과학교실) ;
  • 최은영 (연세대학교 의과대학 내과학교실) ;
  • 이상원 (연세대학교 의과대학 내과학교실) ;
  • 이은직 (연세대학교 의과대학 내과학교실) ;
  • 신동엽 (연세대학교 의과대학 내과학교실)
  • Published : 2012.02.01

Abstract

We encountered a patient with systemic lupus erythematosus that manifested as anemia and thrombocytopenia during antithyroid drug treatment. A 39-year-old woman with Graves' disease was admitted with anemia and thrombocytopenia. She had been treated with propylthiouracil, but had switched to methimazole one month prior to admission. We evaluated many possible causes and found that the patient had renal disorder and hematologic disorder, and was positive for antiphospholipid and antinuclear antibodies. She was diagnosed with systemic lupus erythematosus associated with Graves' disease and was successfully treated with corticosteroids.

저자들은 항갑상선제 치료 중 빈혈과 혈소판감소증으로 발현된 전신성홍반성낭창을 경험하였다. 그레이브스병이 있는 39세 여자 환자가 빈혈과 혈소판감소증으로 입원하였다. 환자는 안티로이드로 치료하다 입원 한 달 전 메티마졸로 변경하였다. 가능한 여러 원인에 대해 검사하였고 환자는 신장 이상, 혈액 이상, 항인지질항체와 항핵항체 양성인 것이 발견되었다. 환자는 그레이브스병에 동반된 전신성홍반성낭창으로 진단되었고 스테로이드 치료에 좋은 반응을 보였다.

Keywords

References

  1. Boelaert K, Newby PR, Simmonds MJ, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med 2010;123:183. e181-e189.
  2. Boey ML, Fong PH, Lee JS, Ng WY, Thai AC. Autoimmune thyroid disorders in SLE in Singapore. Lupus 1993;2:51-54. https://doi.org/10.1177/096120339300200109
  3. Park DJ, Cho CS, Lee SH, Park SH, Kim HY. Thyroid disorders in Korean patients with systemic lupuserythematosus. Scand J Rheumatol 1995;24:13-17.
  4. Cooper DS. Antithyroid drugs. N Engl J Med 2005;352: 905-917. https://doi.org/10.1056/NEJMra042972
  5. Antonelli A, Fallahi P, Mosca M, et al. Prevalence of thyroid dysfunctions in systemic lupus erythematosus. Metabolism 2010;59:896-900. https://doi.org/10.1016/j.metabol.2009.10.010
  6. Tajiri J, Noguchi S. Antithyroid drug-induced agranulocytosis: special reference to normal white blood cell count agranulocytosis. Thyroid 2004;14:459-462. https://doi.org/10.1089/105072504323150787
  7. Thomas D, Moisidis A, Tsiakalos A, Alexandraki K, Syriou V, Kaltsas G. Antithyroid drug-induced aplastic anemia. Thyroid 2008;18:1043-1048. https://doi.org/10.1089/thy.2008.0097
  8. Moreb J, Shemesh O, Shilo S, Manor C, Hershko C. Transient methimazole-induced bone marrow aplasia: in vitro evidence for a humoral mechanism of bone marrow suppression. Acta Haematol 1983;69:127-131. https://doi.org/10.1159/000206873
  9. Ushiki T, Masuko M, Nikkuni K, et al. Successful remission of Evans syndrome associated with Graves' disease by using propylthiouracil monotherapy. Intern Med 2011;50:621-625. https://doi.org/10.2169/internalmedicine.50.4319
  10. Singh NP, Prakash A, Garg D, et al. Aplastic anemia complicating systemic lupus erythematosus: successful management with cyclosporine. Rheumatol Int 2004;24: 40-42. https://doi.org/10.1007/s00296-003-0318-z